A Clinical Trial Research Agreement (CTRA) or Clinical Trial Agreement (CTA) is the primary legal document governing the relationship between a pharmaceutical or biotech sponsor (or its CRO) and the clinical site conducting a clinical trial. These agreements address intellectual property ownership, indemnification, publication rights, payment, and the regulatory obligations of each party. They are among the most heavily negotiated contracts in the pharmaceutical industry, and the stakes are significant: a poorly drafted CTRA can result in IP disputes, enrollment delays, cost overruns, and liability exposure that persists long after the trial concludes.

At Lopes Law LLC, Anthony Lopes, Esq. reviewed and negotiated CTRAs at Merck’s clinical trials launch department through PRA Pharmaceuticals, a global CRO. This guide covers the key provisions every CTRA must address, the standard industry positions on IP and indemnification, and how payment structures work in clinical site agreements.

What Are the Key Parties in a Clinical Trial Agreement?

Understanding who signs the CTRA and what role each party plays is essential to understanding the contract’s structure. CTRAs routinely involve four distinct parties, each with different obligations and interests.

The Sponsor

The sponsor is the pharmaceutical or biotech company that holds the IND (Investigational New Drug Application) and is responsible for the clinical trial under FDA regulations. The sponsor is ultimately accountable for the trial’s conduct, safety reporting, and regulatory compliance. In the CTRA, the sponsor typically owns the trial data, bears indemnification obligations for the investigational product and protocol design, and controls the publication of study results.

The CRO (Contract Research Organization)

A CRO often acts as the sponsor’s agent in CTRA negotiations and may execute agreements on the sponsor’s behalf under a delegated authority arrangement. The CRO may be named as a party to the CTRA, or it may operate under the sponsor’s name pursuant to a sponsor-CRO services agreement. The CTRA must clearly address whether the CRO has authority to bind the sponsor and what happens to site obligations if the sponsor-CRO relationship terminates mid-trial.

The Institution

The institution is the hospital, academic medical center, university, or private practice organization that employs the Principal Investigator and provides the clinical site. Academic medical centers typically have dedicated clinical trials offices that handle CTRA negotiations and have standard institutional templates that can differ significantly from sponsor templates. These negotiations are often the longest phase of clinical trial startup, with timelines of 6 to 16 weeks being common at major academic centers.

The Principal Investigator (PI)

The PI is the physician or researcher who conducts the trial at the clinical site. In most CTRAs, the PI’s obligations are covered by the institution’s agreement; the PI is not a separate party. However, some CTRAs include a PI-specific signature page and separate PI obligations for protocol compliance, IRB maintenance, and adverse event reporting. At Lopes Law LLC, we advise sponsors to ensure that PI obligations are clearly stated, particularly for adverse event reporting timelines.

What Intellectual Property Provisions Should Every CTRA Address?

IP ownership disputes are among the most common and expensive consequences of poorly drafted CTRAs. The CTRA must clearly address ownership of every category of IP that may be created during the trial.

Background IP

Background IP is each party’s pre-existing intellectual property. The CTRA must clearly state that each party retains ownership of its background IP and that nothing in the agreement transfers ownership of background IP to the other party. The definition of background IP should be written carefully to avoid inadvertently capturing improvements or derivatives of existing technology that are actually trial-generated.

Foreground IP (Trial IP)

Foreground IP is the intellectual property created during the performance of the clinical trial. The standard industry position is that the sponsor owns all trial data, case report forms, statistical analyses, and inventions related to the investigational drug. This position reflects the sponsor’s investment in the drug and regulatory responsibility for the data.

Institutions typically accept sponsor ownership of drug-related IP but retain rights to inventions made solely by institutional investigators that are independent of the investigational drug. This carve-out is reasonable; if a surgeon at a clinical site invents a new surgical technique while conducting a trial of an unrelated drug, that invention belongs to the institution. The CTRA must clearly define the boundary between drug-related IP (owned by sponsor) and independent investigator IP (retained by institution).

Publication Rights

Academic institutions require publication rights to fulfill their academic and scientific mission. This is a non-negotiable institutional requirement at virtually every academic medical center. Sponsors require a pre-publication review period to identify patentable information before the results become public prior art.

The standard pre-publication review period is 30 to 60 days. Sponsors typically request 60 days; institutions typically propose 30 days. The CTRA must also address what happens if the sponsor identifies patentable information during review: the institution must agree to delay publication for an additional period (typically 30 to 90 days) to allow the sponsor to file a patent application.

What Indemnification Structure Is Standard in Clinical Trial Agreements?

Indemnification is the most negotiated section of virtually every CTRA. The fundamental allocation of liability between sponsors and institutions follows a consistent industry pattern, but the carve-outs to each party’s obligations are where negotiations become most difficult.

Sponsor Indemnification Obligations

The sponsor indemnifies the institution and its investigators against third-party claims arising from: (1) the investigational product itself, including its known and unknown effects; (2) the protocol design, including any design defect that causes subject injury; and (3) the sponsor’s own negligence in performing its obligations under the CTRA.

This is the foundation of the regulatory bargain: the sponsor controls the drug and the protocol, so the sponsor bears the liability for drug-related and protocol-related injuries. Without this indemnification, few academic medical centers would agree to conduct clinical trials.

Institution Indemnification Obligations

The institution indemnifies the sponsor for claims arising from: (1) the institution’s or PI’s negligence in conducting the trial, including failure to follow the protocol; (2) deviations from the protocol made without sponsor approval; (3) IRB non-compliance; and (4) failure to maintain adequate informed consent procedures for enrolled subjects.

The institution’s indemnification reflects its control over the site operations and investigator conduct. If an adverse event results from the PI’s deviation from the protocol (administering the wrong dose, enrolling an ineligible subject), the institution bears the liability for that deviation.

Insurance Requirements

Sponsors typically require sites to maintain professional liability (malpractice) insurance and general liability insurance at specified minimum limits, typically $1 million per occurrence and $3 million aggregate for professional liability. Academic medical centers are typically self-insured or carry commercial insurance that satisfies these requirements. The CTRA should require insurance certificates and name the sponsor as an additional insured where possible.

How Are Clinical Trial Sites Paid Under CTRAs?

Payment structures in CTRAs follow industry conventions, but the specific amounts are negotiated based on the protocol complexity, subject population, and institutional overhead rates.

Per-Subject Payment Structure

The dominant payment structure is per-subject, per-milestone. The site is paid for each subject completing specific protocol milestones: screening, enrollment/randomization, each scheduled study visit, protocol procedures (specific laboratory tests, imaging), and a final study completion visit. The sponsor or CRO develops a per-subject budget based on the protocol schedule; the site reviews and negotiates based on actual costs.

Institutional Overhead

Academic medical centers typically add institutional overhead charges on top of direct per-subject costs. These overhead rates vary widely: 25 percent to 65 percent of direct costs, depending on the institution’s overhead calculation methodology and federal indirect cost rate agreements. The overhead negotiation is often the most contentious budget element and can add weeks to CTRA startup.

Pass-Through Costs

Some protocol-required activities are not included in the per-subject budget and are handled as pass-through costs: specialty imaging, central laboratory tests not performed at the site, patient transportation reimbursements, and specialty consultations. The CTRA should clearly define what constitutes a pass-through cost and the process for reimbursement.

Startup Payments

Many CTRAs include a startup payment (sometimes called an initiation fee or site activation fee) to cover costs incurred before the first subject is enrolled: IRB submission fees, protocol training costs, site initiation visit preparation, and staff time for contract and budget review. Startup payments are non-refundable if the trial proceeds to site activation.

Client Scenario: The Publication Period That Held Up a Trial

A biotech sponsor’s CTRA template included a pre-publication review period of 15 days. This was a carryover from a prior agreement where the sponsor had negotiated a particularly short review period with a smaller clinical site. The academic medical center the sponsor was now engaging had a firm institutional policy requiring a minimum 60-day review period for all clinical trial publications.

The parties exchanged redlines on the publication section for four weeks. Neither side was willing to compromise significantly: the sponsor needed time to evaluate patentable results before disclosure; the institution needed a defined and not excessively long review period to protect its academic publication rights. The dispute over this single provision held up the clinical trial startup by 6 weeks and delayed first patient enrollment accordingly.

At Lopes Law LLC, we advise sponsors and CROs to prepare their standard CTRA positions in writing before negotiations begin. Knowing in advance what provisions are truly non-negotiable (and which ones can be compromised) allows negotiations to conclude faster. The publication review period is almost always negotiable; the sponsor’s position should be calibrated to what is genuinely needed for patent prosecution, not to an arbitrary maximum that will simply prolong negotiations.

What Other Key Provisions Does a CTRA Need?

Beyond IP, indemnification, and payment, a well-drafted CTRA must address several additional areas that are frequently under-negotiated.

Adverse Event Reporting

The CTRA must specify the site’s reporting obligations for adverse events (AEs), serious adverse events (SAEs), and suspected unexpected serious adverse reactions (SUSARs). The reporting timelines must align with IND safety reporting requirements under 21 CFR 312.32 and the protocol’s safety monitoring plan. A CTRA that is vague about AE reporting timelines can create compliance gaps that result in IND safety reporting violations.

Monitoring and Audit Rights

The sponsor (and, by extension, FDA) must have the right to monitor and audit the clinical site during and after the trial. The CTRA should specify the sponsor’s monitoring rights, the site’s obligations to facilitate monitoring visits, and the site’s obligations to maintain study records for the required retention period (typically the life of the IND plus 2 years after marketing approval, or 2 years after the IND is discontinued).

Subject Injury Compensation

The CTRA must address what happens if a trial subject suffers an injury caused by participation in the trial. Federal regulations require that the informed consent form tell subjects whether medical treatment is available and who pays for it. The CTRA must be consistent with the consent form: if the sponsor agreed to pay for trial-related injuries in the consent form, the CTRA must include a corresponding obligation.

For additional information on CRO contracting and how clinical trial agreements intersect with CRO service agreements, see our guide on CRO Contracting: Negotiating Clinical Trial Service Agreements. For pharmaceutical NDAs that precede clinical trial agreements, see our post on Pharmaceutical NDAs: What Biotech and Pharma Companies Need to Know. For confidentiality agreement issues specific to pharma development, see Confidentiality Agreements in Pharmaceutical Development.

Reach out, we are friendly. Call now for a free consultation at (267) 777-9117 or schedule your free 20-minute consultation online.